GAMMA Investing’s Gyre Therapeutics GYRE Stock Holding History

GAMMA Investing’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-146	Closed	-$962	–	4361
2026 Q2	$962	Buy	146 +64	+78%	+$436	﹤0.01%	3889
2026 Q1	$572	Buy	+82	New	+$637	﹤0.01%	3926
2025 Q3	–	Sell	-124	Closed	-$911	–	3883
2025 Q2	$911	Sell	124 -112	-47%	-$977	﹤0.01%	3549
2025 Q1	$1.82K	Buy	236 +224	+1,867%	+$2.46K	﹤0.01%	3433
2024 Q4	$145	Buy	+12	New	+$154	﹤0.01%	3742

Other funds holding GYRE

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

GAMMA Investing's GYRE Position: Q3 2026 in Review

GAMMA Investing sold out of Gyre Therapeutics (GYRE) in Q3 2026, closing a stake of 146 shares — an estimated $962 sold.

GAMMA Investing first reported a position in GYRE in Q4 2024 and held it in 5 quarters. The position peaked at $1.82K in Q1 2025. 7 funds tracked by Wall St. Rank hold GYRE as of Q3 2026.

GAMMA Investing reported no remaining Gyre Therapeutics position as of Q3 2026 after selling out during the quarter.
GAMMA Investing sold 146 Gyre Therapeutics shares in Q3 2026, an estimated $962.
GAMMA Investing first reported a position in Gyre Therapeutics in Q4 2024 and held it in 5 quarters.
GAMMA Investing's Gyre Therapeutics position peaked at $1.82K in Q1 2025.
7 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.